Completed PHASE2 INTERVENTIONAL 2-arm NCT00130442

Trial of PI-88 With Dacarbazine in Patients With Metastatic Melanoma

A Phase II Study of PI-88 With Dacarbazine in Patients With Metastatic Melanoma

Sponsor: Cellxpert Biotechnology Corp.

Conditions Melanoma

Interventions PI-88 and dacarbazine dacarbazine or DTIC

Updated 8 times since 2017 Last updated: Jun 21, 2022 Started: Jun 30, 2005 Primary completion: Oct 31, 2010 Completion: Oct 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00130442, this PHASE2 trial focuses on Melanoma and remains completed. Sponsored by Cellxpert Biotechnology Corp., it has been updated 8 times since 2005, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jul 2022 — Jul 2024 [monthly]

Completed PHASE2
Feb 2021 — Jul 2022 [monthly]

Completed PHASE2
Jan 2021 — Feb 2021 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Jun 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Cellxpert Biotechnology Corp.
Medigen Biotechnology Corporation

Data source: Cellxpert Biotechnology Corp.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Auchenflower, Australia , Camperdown, Australia , Denver, United States , Nashville, United States , Perth, Australia , Sydney, Australia , Townsville, Australia , Tucson, United States , Wodonga, Australia , Woodville, Australia and 1 more location